Surgery fit for a human, helps a gorilla feel more in his prime – WGN-TV

Please enable Javascript to watch this video

BROOKFIELD, Ill. - 49 years is not often considered "elderly. That is, unless you are a gorilla. At 49, in the primate world, if you are still alive, you are most certainly, living out your golden years.

One such gorilla at the Brookfield Zoo is doing just that.

Ramar is an aging Silverback gorilla and is slowing down every day because his knees are failing.

At 375 pounds and decades of wear and tear veterinarians compare his physical state to an NFL player in their 80s.

So doctors declared surgery is a must to clean out and even improve the aging knees of this incredible animal.

Dr. Michael Adkesson at the Brookfield Zoo invited Dr. Mukund Komanduri, an MD and orthopedic surgeon, to help him get Ramar back on his feet and moving more comfortably again.

"Its interesting. A gorilla knee is just like a human knee probably about the size of a linebacker's knee by a 300 pound guy, Dr. Komanduri said.

Six veterinarians and one human doctor along with 25 or so support staff got Ramar sedated and set for surgery in what was a very busy operating room.

First, there was some fairly routine dental work that included pulling a bad molar.

But the real task was tackling those nagging knees by performing a bilateral arthroscopy, partial removal of the gorilla's meniscus and then injections with synthetic lubricants and a platelet rich plasma to reduce inflammation.

There are minimally invasive procedures medical teams knew were necessary after Ramar stopped moving around his exhibit the way he used to.

After drugs like Lyrica and Celebrex stopped providing relief, it was time for another approach. The apes are taking meds like humans and now the gorillas in captivity are living longer just like us, too. The surgery took between two and three hours to complete. Ramar was wheeled back to his habitat and the team working on him are hopeful their efforts will give this old primate new purpose in his retirement years.

"Hes in fantastic health overall and we expect him to bounce back from this procedure very quickly," Dr. Adkesson said.

More information at Brookfield Zoo.

41.834102 -87.833503

Read more from the original source:
Surgery fit for a human, helps a gorilla feel more in his prime - WGN-TV

LMU-DCOM student selected for research project – The Middlesboro Daily News

Courtesy of LMU Shannon Strader, an osteopathic medical student at LMU-DCOM poses in front of the Shirley Ryan Ability Lab in Chicago.

HARROGATE, Tenn. Shannon Strader, a first-year medical student at Lincoln Memorial University-DeBusk College of Osteopathic Medicine, is one of 12 students from across the nation selected to participate in the summer externship program at Shirley Ryan AbilityLab in Chicago.

Strader will spend eight-weeks this summer working in the Department of Physical Medicine and Rehabilitation at Shirley Ryan AbilityLab which has been ranked as the top rehabilitation hospital in America since 1991 by U.S. News and World Report. During the program, students spend two, four-week rotations on separate inpatient rehabilitation services and have the opportunity to observe and participate in related clinical activities. By the end of the externship, each student is expected to write a research paper and present their project to the extern group and invited departmental faculty.

Since my twin sister, Lauryn, passed away from Cerebral Palsy (CP) I have always wanted to research CP. It is what has inspired me to become a doctor and to be an advocate for families confronting CP, Strader said.

Strader attended the University of WisconsinMadison for her undergraduate studies specifically to do research at James A. Thomson Stem Cell and Regenerative Medicine Center. James A. Thomson is an American developmental biologist known as the father of stem cells for being the first person to derive a human embryonic stem cell.

Naturally, as soon I became a medical student I wanted to apply to externship programs dealing specifically with CP research, Strader said. The Shirley Ryan AbilityLab was my first choice, because they are the top rehabilitation facility in the country. People from all over the world come to the AbilityLab to receive care. Im lucky to learn from the best minds in the field.

The summer externship program is sponsored by the Department of Physical Medicine and Rehabilitation of Northwestern University Medical School. Students from both allopathic and osteopathic accredited medical schools across the United States apply for the program. Additionally, each student selected is awarded a $3,000 stipend for participating in the program.

The Shirley Ryan AbilityLab, formerly the Rehabilitation Institute of Chicago (RIC), is the global leader in physical medicine and rehabilitation for adults and children with the most severe, complex conditions from traumatic brain and spinal cord injury to stroke, amputation and cancer-related impairment. The Shirley Ryan AbilityLab expands and accelerates leadership in the field that began at RIC in 1953 its care and research designated the No. 1 Rehabilitation Hospital in America by U.S. News & World Report every year since 1991. Upon opening in March 2017, the $550 million, 1.2-million-square-foot Shirley Ryan AbilityLab became the first-ever translational research hospital in which clinicians, scientists, innovators and technologists work together in the same space, surrounding patients, discovering new approaches and applying (or translating) research real time. Applied research focuses particularly in the areas of neuroscience, bionic medicine, musculoskeletal medicine and technology transfer. This unique model enables patients to have 24/7 access to the brightest minds, the latest research and the best opportunity for recovery. For more information, go to http://www.sralab.org.

Courtesy of LMU Shannon Strader, an osteopathic medical student at LMU-DCOM poses in front of the Shirley Ryan Ability Lab in Chicago.

http://www.middlesborodailynews.com/wp-content/uploads/2017/07/web1_shannon-strader-web.jpgCourtesy of LMU Shannon Strader, an osteopathic medical student at LMU-DCOM poses in front of the Shirley Ryan Ability Lab in Chicago.

.

Read the original post:
LMU-DCOM student selected for research project - The Middlesboro Daily News

Treating Asthma with Stem Cells | Technology Networks – Technology Networks

A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma.

The Monash Biomedicine Discovery Institute (BDI) scientists provided the experimental expertise to test Cynata Therapeutics induced pluripotent stem cell-derived mesenchymal stem cells (MSCs) in a model of experimental asthma. Induced pluripotent stem cells are a type of pluripotent stem cell that can be generated directly from adult cells; they have the ability to be differentiated into a variety of tissue types and, in this case, MSCs that can regenerate damaged lung tissue.

Lead researchers Associate Professor Chrishan Samuel and Dr Simon Royce tested the efficacy of the MSCs on three key components of asthma in a preclinical model of chronic allergic airways disease: inflammation; airway remodeling (structural changes that occur in lungs as a result of prolonged inflammation); and airway hyperresponsiveness (the clinical symptom of asthma).

The study, published in the FASEB Journal, found that the MSCs could effectively reduce inflammation, reversed signs of airway remodelling and completely normalised airway/lung fibrosis and airway hyperresponsiveness, particularly when delivered intranasally.

It concluded that they may provide a novel stand-alone therapy or an adjunct therapy for groups of asthma sufferers who do not respond to current (corticosteroid) therapy.

Most importantly, what we found was you can treat fibrosis (hardening or scarring of the lung) very effectively, said Associate Professor Samuel, who heads the Monash BDIs Fibrosis Laboratory.

When weve tested other types of stem cells they havent been able to fully reverse scarring and lung dysfunction associated with asthma weve had to combine them with anti-scarring drugs to achieve that. These cells were remarkable on their own as they were able to effectively reverse the scarring that contributes to lung dysfunction and difficulty in breathing, he said.

One in nine - or around 2.5 million- Australians have asthma.

Further research will be conducted to test the MSCs in combination with, or compared to a clinically-used corticosteroid. Clinical trials using the cells as a novel target for asthma are then envisaged.

Cynata Therapeutics Limited is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus stem cell technology platform.

This article has been republished frommaterialsprovided by Monash University. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Royce, S. G., Rele, S., Broughton, B. R., Kelly, K., & Samuel, C. S. (2017). Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease. The FASEB Journal. doi:10.1096/fj.201700178r

See the original post here:
Treating Asthma with Stem Cells | Technology Networks - Technology Networks

Evotec in neurology iPSC drug discovery collaboration with stem-cell specialist Censo – FierceBiotech

Evotec has reached a collaboration with Censo Biotechnologies, using the latters patient-derived induced pluripotent stem cells (iPSC) to expand its platform for drug discovery.

Scientists get iPSCs by reprograming human adult somatic cells to make them resemble embryonic stem cells, which can become any cell type of the body. For this alliance, Censo will use its donors sourcing and cell reprograming technologies to create a bespoke library of hundreds of patient-derived iPS cell lines, and Evotec will use them for target validation, drug screening, drug metabolism and pharmacokinetics analyses.

These stem cell-like cells created from people suffering from a disease allow researchers to replicate or mimic the disease ex vivo under lab conditions. This approach is particularly helpful for understanding of the mechanism of diseases such as Parkinsons and Alzheimers. The current contract between Evotec and Censo, with an initial two-year term, will first focus on central nervous system diseases, an area that both companies excel in.

RELATED:Axiogenesis in stem cell collab with ion channel expert Metrion

The Hamburg, Germany-based Evotec has been involved in neurological research for over two decades, having taken part in the discovery process of about a dozen preclinical candidates. The CROs expertise spans some key target classes such as enzymes, GPCRs and ion channels, and in therapeutic areas of neurodegenerative diseases, neuroinflammation, among others.

Censo is the product of a 2016 merger between Roslin Cellab and Roslin Cell Sciencestwo spinouts from the Roslin Institute both focused on using stem cells for drug discovery. Operating from its Edinburgh and Cambridge facilities in the U.K., Censo can generate iPSCs from large cohorts of samples for drug researches, and usually partner with other companies for assay development.

See more here:
Evotec in neurology iPSC drug discovery collaboration with stem-cell specialist Censo - FierceBiotech

The Stem Cell Revolution – Seeking Alpha

By Manisha Samy, ARK analyst

Discovered nearly thirty years ago in 1988[1], stem cell technology has failed to transform the field of regenerative medicine until now. After delivering only one treatment during three decades of development, stem cell technology could finally become the all-purpose tool for repairing the body, thanks to rapid and precise genome editing techniques such as CRISPR and TALENs. Several obstacles in stem cell technology- high costs, safety concerns, and bioethical considerations are beginning to fall away. In particular, the introduction of induced pluripotent stem cells (iPSCs) eliminated many of the initial bioethical concerns stirred by the the source of stem cells. Now, advances in genome-editing is accelerating the pace of progress.

Stem cells exist in a state of possibility. Two key markers of stem cells are 1) the ability to self-renew and 2). The ability to become any specialized cell. Broadly speaking, a stem cell can evolve into any of the ~200 specialized human cell types, as illustrated in Figure 1. Directing stem cells to become any one of the 200 cell types has proven challenging.

Moreover, before the introduction of iPSCs, which are derived from adult cells, most human stem cells were sourced from human embryos or cord blood. The political and ethical controversies surrounding embryonic research curtailed stem cell funding. As a result, after a quarter century of research, bone marrow transplantation is the only FDA-approved stem cell application in the United States.

Figure 1

Breakthroughs in cheap, rapid genome-editing have re-invogored momentum in stem cell research. As shown in Figure 2, the number of publications on PubMed mentioning both stem cells and gene-editing hit a tipping point upon the discovery of CRISPR in 2012, three years after the first instance of precise TALENs-based genome-editing in human cells. Based on the current trajectory, ARK estimates that the number of scientific publications including both genome-editing and stem cells will approach 300 this year, accounting for nearly 20% of the total number of publications.

Figure 2

As illustrated in Figure 3, while the discovery of iPSC cells in 2006 boosted stem cell research noticeably beginning in 2008, the introduction of CRISPR in 2012 has further catapulted the stem cell field, with combined gene-editing and stem cell publications taking share.

Figure 3

Why Is The Addition of Gene-Editing So Important to Stem Cell Research and Therapy?

Figure 4

Ultimately, CRISPR edited iPSCs should unlock the code to human disease at a cellular level. Three public CRISPR companies are in a good position for the impending stem cell revolution. Editas Medicine (EDIT) signed a stem cell pact with GlaxoSmithKline (GSK) and Biogen (BIIB) for next-gen stem-cell therapies; CRISPR Therapeutics (CRSP) CRSP),+Casebia+Therapeutics+Sign+Commercial+License+Agreement+to+MaxCyte/12664463.html" rel="nofollow">licensed a CRISPR delivery mechanism for blood stem cells and has formed a CRISPR joint venture with Bayer (BAYZF); and Intellia Therapeutics (NTLA) has partnered with biotech giant Novartis NVS to focus on stem-cell based therapies. These companies, among others, finally might unleash the limitless possibilities that stem cells once promised in regenerative medicine, extending human life spans considerably.

Notes

[1] The Weissman Lab at Stanford University first isolated hematopoietic (blood) stem cells from mice bone marrow in 1988; it would be another decade before human stem cells were isolated.

Disclosure: ARK's statements are not an endorsement of any company or a recommendation to buy, sell or hold any security. For a list of all purchases and sales made by ARK for client accounts during the past year that could be considered by the SEC as recommendations, click here. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. For full disclosures, click here.

Disclaimer: 2017, ARK Investment Management LLC ("ARK"). All content is original and has been researched and produced by ARK unless otherwise stated. No part of ARK's original content may be reproduced in any form, or referred to in any other publication, without the express written permission of ARK. The content is available for informational purposes only and is subject to change without notice. All statements made regarding companies or securities or other financial information on this site or any sites relating to ARK are strictly beliefs and points of view held by ARK or the third party making such statement and are not endorsements by ARK of any company or security or recommendations by ARK to buy, sell or hold any security. For a list of all purchases and sales made by ARK for client accounts during the past year that could be considered by the SEC as recommendations, click here. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. For full disclosures, please see the Terms of Use for this site.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Read this article:
The Stem Cell Revolution - Seeking Alpha

When C9ORF72 Silences U2, Spliceosomes Can’t Find What They … – Alzforum

30 Jun 2017

Expanded C9ORF72 hexanucleotide repeats cause many cases of amyotrophic lateral sclerosis and frontotemporal dementia, but exactly how these expansions work their mischief remains a mystery. Researchers have proposed several different pathogenic mechanisms, including that aberrant dipeptide repeat (DPR) proteins made from the expansion interfere with mRNA splicing. In the June 13 Cell Reports, researchers led by Robin Reed at Harvard Medical School describe how this could happen. Using in vitro assays, they found that DPRs prevented spliceosome assembly through interactions with one portion of this splicing complex, the U2 small nuclear ribonucleoprotein (snRNP) particle. In cells, C9ORF72 DPRs caused the U2 complex to mislocalize to the cytoplasm, away from splicing sites in the nucleus. Subsequent bioinformatics analyses suggested that disruption of U2 function accounts for about 40 percent of the mis-splicing seen in C9ORF72 patient cells, Reednoted.

The data for the mechanism are compelling, but it remains unclear how much it contributes to neurotoxicity, noted Johnathan Cooper-Knock at the University of Sheffield, England, in an email to Alzforum. He was not involved in the research. One way to address this might be to examine its correlation with clinical phenotype, he suggested (see full commentbelow).

In control motor neurons (left), the U2 splicing complex (red) occupies the nucleus, but in C9ORF72 motor neurons (right), much of it lurks in cytoplasm. [Courtesy of Cell Reports, Yin etal.]

Previous research had found that C9ORF72 expansions caused mis-splicing in cultured cells (see Aug 2014 news; Conlon et al., 2016). In one study, the degree of this mis-splicing correlated with faster ALS progression (Cooper-Knock et al., 2015).The papers proposed different explanations for how mis-splicing occurred, however, from dipeptide repeat proteins physically gumming up the splicing machinery in the nucleolus to C9ORF72-expanded RNAs sequestering crucial splicing factors such asHNRNPH.

To try to nail down the mechanism, first author Shanye Yin used a cell-free system developed in the Reed lab that combined nuclear extract from HeLa cells with a DNA template for the fly Ftz gene. In this assay, the Ftz gene is transcribed by RNA polymerase and the resulting RNA is then spliced to yield mature transcript. However, when the authors added a 20-repeat length of the toxic DPRs glycine-arginine (GR) or proline-arginine (PR), splicing ground to a halt. The effectiveness of the block depended on the dose of DPR. Further analysis showed that in the presence of DPRs, the spliceosome failed to assemble properly. C9ORF72 RNA, by contrast, had no effect on splicing in thissystem.

The authors next searched for proteins that associated with GR and PR using pull-down assays, and identified these interactors by mass spectrometry. The most common were components of the U2 snRNP, although other proteins were present as well. The list of interacting proteins largely matches that seen in previous proteomic screens of DPRs, noted Paul Taylor at St. Jude Childrens Research Hospital in Memphis, Tennessee. That gives us confidence in the data, he toldAlzforum.

The findings suggested a direct interaction of DPRs with the splicing machinery in vitro. Would the same thing happen in patients? The authors examined motor neurons made from induced pluripotent stem cells of people who carried the C9ORF72 expansion. They were surprised to find U2 snRNP lingering outside the nucleus in about half these cells (see image above). It was unclear if the complex leaked out of the nucleus, or simply never made it inside in the first place, Reed noted. U2 snRNP is assembled in the cytoplasm, and faulty transport across the nuclear membrane has quickly become a hallmark of C9ORF72 disease, with many nuclear proteins, such as TDP43 and FUS, getting stuck en route (Jan 2010 news;Aug 2015 news).DPRs are known to build up in the cytoplasm, suggesting they could be sequestering the U2 snRNP there. Overexpressing PR in HeLa cells also caused U2 snRNP to loiter in cytoplasm, supporting a direct causal role for these peptides in U2 mislocalization. This was specific to U2, as other components of the splicing apparatus stayed confined to thenucleus.

The authors next wondered how big a role U2 mis-splicing might play in disease. U2 snRNP normally helps splice about one-quarter of all transcripts (see Kfir et al., 2015). Analyzing published RNA expression data from C9ORF72 cerebella and frontal cortices (Prudencio et al., 2015), the authors found that the mis-spliced mRNA was enriched for U2-dependent transcripts. Altogether, U2 snRNP may account for nearly half of the mis-splicing in these cells, they calculated. They saw a much smaller role for HNRNPH-dependent splicing. Notably, in brain samples from sporadic ALS cases, U2-dependent transcripts were no more likely to be mis-spliced than any others, indicating this mechanism is specific for C9ORF72expansions.

In theory, mis-splicing could lead to toxicity by knocking out essential proteins. In support of this, the authors found numerous transcripts involved in mitochondrial function and gene expression among the disrupted set. Both of these processes are known to be perturbed inALS.

However, DPRs sequester other proteins as well, which may play an equally important role in damaging cell function, Taylor noted. Many of the proteins bound by DPRs contain low-complexity domains. Such proteins are now believed to be crucial in assembling many cellular organelles (Oct 2015 webinar; May 2017 conference news).Madolyn BowmanRogers

Make a Comment

To make a comment you must login or register.

More here:
When C9ORF72 Silences U2, Spliceosomes Can't Find What They ... - Alzforum

Cure for ageing could lie in gene therapy | WIRED UK

Leon Csernohlavek

In September 2015, Elizabeth Parrish flew from Seattle to Colombia to receive an experimental treatment.

She had spent more than two years studying literature, talking to experts, and had decided to undergo gene therapy a treatment for genetic disorders that adds genes into cells to replace those that are faulty or absent. She ordered the therapeutic cells months in advance and arranged for a technician to administer the therapy in a clean room within a short distance of a hospital, in case she suffered a bad immune response. The gene therapy was shipped in a closed container and administered via an IV over approximately five hours. Parrish remained under observation for a few days and then flew home.

Was I anxious afterwards? Yes, Parrish says. I was definitely looking for indications that anything was wrong with my body. I was acutely aware of every ache and pain. She had become the first person to subject herself to gene therapy for the disease that affected her. Her condition? Ageing.

Subscribe to WIRED

In January 2013, Liz Parrish son was diagnosed with Type 1 diabetes. Every few days, he would have some devastatingly low blood sugar levels, Parrish says. I was continually reminded that we as humans spend a lot of time trying to pretend as if our death is not eminent. She remembers being told that her son was lucky because diabetes was treatable. I was really hit hard by the time I spent in children's' hospitals, Parrish says. She had read about the promises of modern medicine, in particular, gene therapy. I began trying to figure out why nothing was translating to hospitals where kids were dying.

Parrish began attending medical conferences on her own. I found this conference in Cambridge that looked to be about genetics, Parrish says. It turned out to be about longevity. There she learned how gene modifications had already extended the normal lifespan of worms up to 11 times and of mice by five times. It made me realise that if ageing was a disease and everyone was suffering from an illness, the fastest way to fund this research would be to essentially educate the world that was the case and get them to put money behind finding a cure, Parrish says.

At that point, Parrish, who up until then had been working part-time for software companies, started her own company, BioViva, to expedite therapeutics and give access to patients. Why did so many patients have to wait, suffer and die? Parrish asks. We became so risk adverse that patients die waiting for treatment. We have to change that drastically. We have millions of terminally ill patients on the planet right now. These patients should have access to the most promising therapeutics that don't have a myriad of off-target effects. There is no artificial intelligence or meta analysis of these therapies that is going to replace what happens in the human body. And we let people die because we're so concerned that a therapy might kill them. This is lawyering at its absolute worst.

Parrish then made another decision: she was going to try the first therapy on herself. I believed it was the most responsible and ethical thing to do. I believed the company should take its own medicine first before moving onto patients.

Parrish tried two therapies. One was a myostatin inhibitor, a drug designed to increase muscle mass, and the second was telomerase therapy, which lengthens the telomeres, a part of the chromosomes that protect genetic material from damage and allows the replication of DNA. Lengthening the telomeres can, at least in theory, extend cellular lifespan and make cells more resilient to damage.

The telomerase therapy had reversed ageing and extended lifespan in mice, Parrish says. I assumed this was the most promising therapy ever, and it was just sitting in research and wasn't moving forward as a viable option due to what appeared to be patenting issues and a lot of academics sitting on the fence bickering. We will never know unless we get it in humans. It's almost a moot point to try to continue to argue whether it works or not if we never use it. Its just like lemmings walking off the cliff, waiting for someone else to solve the problems.

A few weeks after the treatment, Parrish undertook follow-up exams, conducted by independent third parties. Her telomeres in her white blood cells had lengthened by more than 600 base pairs which, according to Parrish, implies they had extended by the equivalent of 20 years. A full-body MRI imaging revealed an increase in muscle mass and reduction in intramuscular fat. Other tests indicate Parrish now has improved insulin sensitivity and reduced inflammation levels.

The company was built essentially to prove these therapies work or not, Parrish says. Remember BioViva is not a research organisation. We are taking things like gene therapies and using them like technology. We would like to create an open market where people have access to acquiring these technologies, much like you would acquire a cellphone or a computer.

Further tests are being conducted at George Churchs lab in Harvard. Parrish and her team are currently working with other hospital clinics around the world to conduct more safety and feasibility studies in human subjects. I had already put things into perspective that without medicine, my son would be dead and he really was the meaning of my life, Parrish says. I was a person who quite honestly felt I had not really contributed that much to society and this was my opportunity to do so.

See the original post here:
Cure for ageing could lie in gene therapy | WIRED UK

Digital Journal: A Global Digital Media Network – Digital Journal (press release)

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 06/27/2017 -- Market Highlight

Americas Cancer Biological Therapy market is expected to grow at a CAGR of 5.2% during forecasted period of 2017-2023

Americas Cancer Biological therapy market is expected to grow at a steady rate in coming future. There are number of different types of treatment available in the market like chemotherapy, radiotherapy and different drugs therapy, but every therapy has its minor or major side effects. Biological therapies may overcome the side effects like hair loss, weakened immune system which are caused by the other treatment methods. Success rate of all the therapies are same but biological therapy causes less side effects. Cancer can only be cure during 1st stage with a chances of approximately 40-50%.

Biological therapy involves treatment with the help of living organism. Many biological therapy are available for the treatment of cancer. Gene therapy has got a special attention in last few year. Many development and research are been carried out in this field and it can be a better option for the treatment of the cancer. According to National Cancer Institute, 14 million people are suffering from cancer in 2014 which is expected to increase upto 19 million till 2024. The major driving factor for cancer biological therapy market are introduction of new and better antibody, increasing incidence of cancer and less side effect of biological therapy over other optional therapy.

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/591

Key Players for Cancer Biological Therapy Market -Hoffmann-La Roche AG, -GSK, -Merck & Co., -Novartis International AG, Inc., -GlaxoSmithKline Plc, https://www.marketresearchfuture.com/reports/americas-cancer-biologic-therapy-market -Bristol-Myers Squibb, -Eli Lilly, -Amgen Inc., -Spectrum Pharmaceuticals, Inc., -Seattle Genetics, Inc., -Celgene Corporation -others

Segmentation

Americas Cancer Biological Therapy market has been segmented on the basis of-

-By types which comprises of monoclonal antibodies (Naked monoclonal antibodies, Conjugated monoclonal antibodies, other), interferons, interleukins, cancer growth inhibitors (Tyrosine kinase inhibitors, mTOR inhibitors and Proteasome inhibitors), gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others.

-On the basis of end user, market is segmented into hospitals & clinics, cancer research centers, laboratories and others.

-And on the basis of Region market is segmented as US, Canada and Rest of America.

Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on "Americas Cancer Biological Therapy Market Research Report- Forecast To 2022"

Browse full report @ https://www.marketresearchfuture.com/reports/americas-cancer-biologic-therapy-market

Table of Content

1Introduction 1.1 Definition 1.2 Scope Of Study 1.2.1 Research Objective 1.2.2 Assumptions & Limitations 1.2.2.1 Assumptions 1.2.2.2 Limitations 1.3 Market Structure: 2 Research Methodology 2.1Research Process: 2.2Primary Research 2.3Secondary Research: 3Market Dynamics 3.1Drivers 3.2Restraints 3.3Opportunities 3.4Macroeconomic Indicators 4Market Factor Analysis 4.1Porters Five Forces Model 4.2Bargaining Power Of Suppliers 4.3Bargaining Power Of Buyers 4.4Threat Of New Entrants 4.5Threat Of Substitutes 4.6Intensity Of Rivalry 5Market Factor Analysis

Key questions answered in this report -What will the market size be in 2023 and what will the growth rate be? -What are the key market trends? -What is driving this market? -What are the challenges to market growth? -Who are the key vendors in this market space? -What are the market opportunities and threats faced by the key vendors? -What are the strengths and weaknesses of the key vendors?

Related Report Global Blood Transfusion Diagnostics Market Information by Type (Instruments, Reagents), By Application (Blood Grouping, disease Screening), By End users (Hospital, laboratories, Blood Banks, Plasma Fractionation Facilities) - Forecast to 2027.Know more about this report @ https://www.marketresearchfuture.com/reports/blood-transfusion-diagnostics-market

About Market Research Future At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact: Akash Anand, Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India +1 646 845 9312 Email: akash.anand@marketresearchfuture.com

For more information on this press release visit: http://www.sbwire.com/press-releases/respiratory-therapeutic-devices-market-growth-opportunities-key-driving-factors-market-scenario-and-forecast-to-2023-821584.htm

More here:
Digital Journal: A Global Digital Media Network - Digital Journal (press release)

Damaged bone or cartilage? Now, grow your own cells in a lab – Hindustan Times

When 14-year-old Aarav Gulati (name changed on request) met with an accident a couple of years ago while playing football, he injured his knee. A portion of the cartilage was damaged, and doctors used turned to a radical new procedure for a solution. They took Gulatis own cells, grew them in a lab and used them to replace the cartilage and repair the damage in a natural way.

He was an ideal case for the use of regenerative cell therapy that was a fairly new phenomenon in orthopaedic treatment in India, says Dr Yash Gulati, senior joint replacement and spine surgeon, New Delhis Indraprastha Apollo Hospital.

The regenerative cell therapy got US FDA approval this year, and the Apollo group partnered with RMS REGROW, a company that specialises in cell therapy technology, to exclusively offer the treatment to patients in India.

Instead of using artificial implants, the technique helps in healing the bone or cartilage damage in a natural way using a persons own cells to regain normal function. Cultured cells (grown in a lab) are injected into a patient to replace diseased or dysfunctional cells.

Instead of using artificial implants, the technique helps in healing the bone or cartilage damage in a natural way using a persons own cells to regain normal function. Cultured cells (grown in a lab) are injected into a patient to replace diseased or dysfunctional cells. (Illustration: Siddhant Jumde)

A small part of the joint cartilage is taken through a keyhole procedure, and is grown in a special manner to convert it into stem cells in the laboratory, says Dr Gulati. This is then applied on the area showing loss of joint cartilage.

Dr Gulati has so far treated 10 people using this therapy in Apollo, Delhi.

Stem cells lead to growth of joint cartilage in defective areas, and normal new cartilage re-grows. In bone damage, bone marrow cells are harvested, cultured and implanted in the area to be able to re-grow in a healthy way, Dr Gulati says.

In Mumbai, those in need of joint replacement because of injury, wear and tear or other lifestyle and ageing, are also realising that new cartilage can be grown in a lab from ones own cells and used instead of artificial materials.

Chondron or cartilage cell therapy is a patient-specific regenerative medical treatment which naturally regrows original cartilage. The therapy is used for repairing articular cartilage of the knee, ankle and shoulder joints and to help replace missing areas of cartilage.

This is a process where a biopsy of cartilage cells (chondrocytes) is taken from the patients knee, ankle or shoulder, says Satyen Sanghavi, chief scientific officer of Regenerative Medical Services Regrow, a biotechnology company in Mumbai.

Causes of bone or cartilage damage

They are then cultured to grow and multiply in a lab for 3-4 weeks into a surplus population of several million. The cultured cells are then re-implanted in the damaged area in a minimally invasive surgical procedure.

The process comes from eight years of work in cell and tissue therapy research. Chondron ACI is the countrys first cell therapy product.

These cells grow and repair tissue with properties similar to that of normal cartilage present in other joints, says Sanghavi. But replacement alone doesnt solve problems. Patients are expected to follow a rehabilitation program, to help the body adjust to new cells and them get back to day-to-day physical.

Its easy to see the advantages of a process like this. Experts say it may avoid the need for future prosthetic joints replacement (especially partial joint replacement) and allows patients the freedom to continue physical activities as before.

It also poses less risk of disease transmission or infection since it comes from the patients own tissue (no foreign material or metal goes inside the body). It may also halt further progression to osteoarthritis, a common problem with those in need of joint replacement.

The procedure costs Rs.3 to 3.5 lakhs.

In India, more than 500 patients have been treated with both bone and cartilage cell therapy procedures, says Sanghavi.

There is a success rate of more than 95%. During our clinical trials and research, we have treated working professionals, housewives, athletes, army men and mountaineers. Almost all of them have successfully recovered and got back to their active life.

However, this new technique has a flip side, too.

The price could be a bit steep for some because stem cell treatment is expensive; and the treatment gets prolonged as a patient has to wait for some time as cell culture takes time and one cannot bear weight on the affected area while the healing is on. Also, not all patients are suitable for it because it can correct only if damage isnt extensive, says Dr Ankit Goyal, associate professor, Safdarjung Sports Injury Centre (SIC) in Delhi.

Safdarjung Hospital had also treated about 35 patients, who had damaged their cartilage, with the technique a few years ago.

We would send cartilage for culture but only in cases where damage was limited. This is definitely not a substitute for knee or hip replacement procedure where the entire joint is extensively damaged. However, it may prevent the need for replacement later on in life, especially in young patients, he says.

More:
Damaged bone or cartilage? Now, grow your own cells in a lab - Hindustan Times

Is stem cell therapy approved in Singapore? – The Straits Times

Reader Charles Wang wrote to ask if stem cell therapy - the use of stem cells to treat various medical conditions - is approved in Singapore. Mr Wang also asked where one could seek this treatment if it is available. Health reporter Linette Lai answered.

Any new treatment must be backed up by sufficient scientific evidence to ensure that it is safe and effective. However, there is still not enough scientific evidence available for stem cell therapy to be approved as a mainstream treatment in Singapore.

A Ministry of Health spokesman said: "To date, stem cell therapy has not been substantiated by sufficient clinical evidence as a form of mainstream treatment for any diseases or ailments, and it is not available as a treatment in our public hospitals.

"If any registered medical practitioners or institutions want to administer stem cells as a form of medical treatment, it would have to be conducted within the context of clinical trials."

Continue reading here:
Is stem cell therapy approved in Singapore? - The Straits Times